First gene therapy to limp onto EU market

The European Commission has followed the CHMP's recommendation and approved UniQure's gene therapy Glybera (alipogene tiparvovec) in the European Union, but the company is not leaping out of the starting blocks. It says it will begin the commercial roll-out in the second half of 2013.